U
EastWest Bioscience Inc.
EASTH.V
TSX
D
Sell
11/4/2022Downgrade
EastWest Bioscience Inc. (EAST.V) was downgraded to D from D+ on 11/4/2022 due to a noticeable decline in the total return index.
EastWest Bioscience Inc. (EAST.V) was downgraded to D from D+ on 11/4/2022 due to a noticeable decline in the total return index.
D
Sell
10/10/2022Upgraded
EastWest Bioscience Inc. (EAST.V) was upgraded to D+ from D on 10/10/2022 due to a significant increase in the total return index and volatility index.
EastWest Bioscience Inc. (EAST.V) was upgraded to D+ from D on 10/10/2022 due to a significant increase in the total return index and volatility index.
D
Sell
7/28/2022Upgraded
EastWest Bioscience Inc. (EAST.V) was upgraded to D from D- on 7/28/2022 due to an increase in the volatility index and total return index.
EastWest Bioscience Inc. (EAST.V) was upgraded to D from D- on 7/28/2022 due to an increase in the volatility index and total return index.
D
Sell
7/13/2022Downgrade
EastWest Bioscience Inc. (EAST.V) was downgraded to D- from D on 7/13/2022 due to a major decline in the growth index, volatility index and total return index. Earnings per share declined from $0.0165 to -$0.0044.
EastWest Bioscience Inc. (EAST.V) was downgraded to D- from D on 7/13/2022 due to a major decline in the growth index, volatility index and total return index. Earnings per share declined from $0.0165 to -$0.0044.
D
Sell
11/9/2021Upgraded
EastWest Bioscience Inc. (EASTH.V) was upgraded to D from E+ on 11/09/2021.
EastWest Bioscience Inc. (EASTH.V) was upgraded to D from E+ on 11/09/2021.
E
Sell
11/8/2021Downgrade
EastWest Bioscience Inc. (EAST.V) was downgraded to E+ from D on 11/8/2021 due to a decline in the solvency index and valuation index. Debt to equity increased from -4.7 to -4.6.
EastWest Bioscience Inc. (EAST.V) was downgraded to E+ from D on 11/8/2021 due to a decline in the solvency index and valuation index. Debt to equity increased from -4.7 to -4.6.
D
Sell
12/30/2020Upgraded
EastWest Bioscience Inc. (EAST.V) was upgraded to D from D- on 12/30/2020 due to a large increase in the growth index and volatility index. Earnings per share increased from -$0.0032 to -$0.0024.
EastWest Bioscience Inc. (EAST.V) was upgraded to D from D- on 12/30/2020 due to a large increase in the growth index and volatility index. Earnings per share increased from -$0.0032 to -$0.0024.
D
Sell
11/3/2020Downgrade
EastWest Bioscience Inc. (EAST.V) was downgraded to D- from D on 11/3/2020 due to a decline in the volatility index.
EastWest Bioscience Inc. (EAST.V) was downgraded to D- from D on 11/3/2020 due to a decline in the volatility index.
D
Sell
10/19/2020Upgraded
EastWest Bioscience Inc. (EAST.V) was upgraded to D from D- on 10/19/2020 due to an increase in the total return index and valuation index.
EastWest Bioscience Inc. (EAST.V) was upgraded to D from D- on 10/19/2020 due to an increase in the total return index and valuation index.
D
Sell
9/9/2020Downgrade
EastWest Bioscience Inc. (EAST.V) was downgraded to D- from D on 9/9/2020 due to a decline in the total return index and volatility index.
EastWest Bioscience Inc. (EAST.V) was downgraded to D- from D on 9/9/2020 due to a decline in the total return index and volatility index.
D
Sell
7/27/2020Upgraded
EastWest Bioscience Inc. (EAST.V) was upgraded to D from D- on 7/27/2020 due to an increase in the total return index.
EastWest Bioscience Inc. (EAST.V) was upgraded to D from D- on 7/27/2020 due to an increase in the total return index.
D
Sell
7/1/2020Downgrade
EastWest Bioscience Inc. (EAST.V) was downgraded to D- from D on 7/1/2020 due to a large decline in the growth index and solvency index. Earnings per share declined from -$0.0004 to -$0.0032, total revenue declined 50.54% from $203.6 to $100.7, and operating cash flow declined 4.91% from -$38.7 to -$40.6.
EastWest Bioscience Inc. (EAST.V) was downgraded to D- from D on 7/1/2020 due to a large decline in the growth index and solvency index. Earnings per share declined from -$0.0004 to -$0.0032, total revenue declined 50.54% from $203.6 to $100.7, and operating cash flow declined 4.91% from -$38.7 to -$40.6.
D
Sell
5/1/2020Upgraded
EastWest Bioscience Inc. (EAST.V) was upgraded to D from E+ on 5/1/2020 due to a noticeable increase in the solvency index, growth index and volatility index. Earnings per share increased from -$0.0039 to -$0.0004, the quick ratio increased from 0.1 to 0.16, and operating cash flow increased 48.4% from -$75 to -$38.7.
EastWest Bioscience Inc. (EAST.V) was upgraded to D from E+ on 5/1/2020 due to a noticeable increase in the solvency index, growth index and volatility index. Earnings per share increased from -$0.0039 to -$0.0004, the quick ratio increased from 0.1 to 0.16, and operating cash flow increased 48.4% from -$75 to -$38.7.
E
Sell
2/11/2020Downgrade
EastWest Bioscience Inc. (EAST.V) was downgraded to E+ from D- on 2/11/2020 due to a significant decline in the solvency index, volatility index and valuation index. Debt to equity increased from 3.2 to 10.23, and the quick ratio declined from 0.17 to 0.1.
EastWest Bioscience Inc. (EAST.V) was downgraded to E+ from D- on 2/11/2020 due to a significant decline in the solvency index, volatility index and valuation index. Debt to equity increased from 3.2 to 10.23, and the quick ratio declined from 0.17 to 0.1.
D
Sell
4/1/2019Upgraded
EastWest Bioscience Inc. (EAST.V) was upgraded to D- from E on 4/1/2019 due to an increase in the solvency index and valuation index.
EastWest Bioscience Inc. (EAST.V) was upgraded to D- from E on 4/1/2019 due to an increase in the solvency index and valuation index.
E
Sell
1/3/2019Upgraded
EastWest Bioscience Inc. (EAST.V) was upgraded to E from E- on 1/3/2019 due to a noticeable increase in the growth index, solvency index and efficiency index. Earnings per share increased from -$0.0214 to -$0.0071, net income increased 63.27% from -$1.47M to -$540.9, and the quick ratio increased from 3.71 to 5.99.
EastWest Bioscience Inc. (EAST.V) was upgraded to E from E- on 1/3/2019 due to a noticeable increase in the growth index, solvency index and efficiency index. Earnings per share increased from -$0.0214 to -$0.0071, net income increased 63.27% from -$1.47M to -$540.9, and the quick ratio increased from 3.71 to 5.99.
E
Sell
11/19/2018Downgrade
Harbour Star Capital Inc. (EAST.V) was downgraded to E- from E on 11/19/2018 due to a large decline in the solvency index and volatility index.
Harbour Star Capital Inc. (EAST.V) was downgraded to E- from E on 11/19/2018 due to a large decline in the solvency index and volatility index.
E
Sell
10/17/2018None
EastWest Bioscience Inc. (EASTH.V) was downgraded to E from U on 10/17/2018.
EastWest Bioscience Inc. (EASTH.V) was downgraded to E from U on 10/17/2018.
